Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798678 · ClinicalTrials.gov registry record · Phase 1
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT03798678 is a Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03798678, a Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Telaglenastat Hydrochloride
Study Locations (5)
Connecticut
- Yale University - New Haven
Florida
- Moffitt Cancer Center - Tampa
Minnesota
- Mayo Clinic in Rochester - Rochester
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798678
The ClinicalTrials.gov registry entry for NCT03798678 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (25% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03798678 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03798678 about?
NCT03798678 is a clinical study titled "CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma". This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of th...
What is the current status of trial NCT03798678?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-07-08. Estimated completion is 2026-06-30.
What conditions does trial NCT03798678 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Recurrent Multiple Myeloma.
What interventions are being tested in trial NCT03798678?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Telaglenastat Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03798678?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03798678 being conducted?
This trial has 5 study locations across Connecticut, Florida, Minnesota, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.